AIMI — AIM ImmunoTech Income Statement
0.000.00%
Last trade - 00:00- $6.14m
- $4.47m
- $0.17m
Annual income statement for AIM ImmunoTech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.163 | 0.135 | 0.141 | 0.202 | 0.17 |
| Cost of Revenue | |||||
| Gross Profit | -0.643 | -0.715 | 0.141 | 0.16 | 0.139 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.2 | 21.7 | 20.1 | 32.1 | 19.9 |
| Operating Profit | -15 | -21.5 | -19.9 | -31.9 | -19.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.4 | -19.1 | -19.4 | -29 | -17.3 |
| Net Income After Taxes | -14.4 | -19.1 | -19.4 | -29 | -17.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.4 | -19.1 | -19.4 | -29 | -17.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.4 | -19.1 | -19.4 | -29 | -17.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.485 | -0.363 | -0.436 | -0.63 | -0.28 |